| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.83B | — | -0.1% |
| Cost of Revenue | $2.60B | — | +1.4% |
| R&D Expense | $232.0M | — | +26.1% |
| SG&A Expense | $465.0M | — | +20.5% |
| Pre-tax Income | $13.0M | — | -92.0% |
| Income Tax | $4.0M | — | -91.5% |
| Net Income | $7.0M | — | -94.7% |
| EPS (Basic) | $0.01 | — | -90.0% |
| EPS (Diluted) | $0.01 | — | -90.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.60B | -37.8% | -5.4% |
| Inventory | $5.23B | +12.5% | +1.5% |
| Total Assets | $42.04B | -1.7% | -0.0% |
| Total Liabilities | $34.17B | -2.2% | +0.2% |
| Stockholders' Equity | $7.81B | +0.5% | -1.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $35.0M | — | -78.4% |
| Investing Cash Flow | $54.0M | — | +119.3% |
| Financing Cash Flow | -$990.0M | — | +30.4% |